Jan 31, 2020 - Old Dominion's (ODFL) fourth-quarter 2019 results will likely reflect unfavorable impact of a soft freight environment.
Jan 28, 2020 - These three companies are innovators in the development of cancer drugs, and they can also make you a lot of money.
Jan 27, 2020 - The approval includes a new oral suspension version of the drug.
Jan 27, 2020 - Top Stock Analyst Reports for Merck, Broadcom & Sanofi
Jan 27, 2020 - Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Jan 24, 2020 - With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Jan 24, 2020 - Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Jan 24, 2020 - J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Jan 22, 2020 - Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Jan 22, 2020 - Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.